Literature DB >> 9069591

Epidemiology of drug-induced severe skin reactions.

M Mockenhaupt1, E Schöpf.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, sometimes life-threatening skin reactions that are often drug-induced. Unfortunately, the definitions and nomenclature of these severe skin reactions have been confusing, and thus various publications on this issue can hardly be compared. After several attempts have been made to clarify this situation, a consensus definition published in 1993 suggests the differentiation between erythema exsudativum multiforme majus (EEMM) and SJS, as well as an overlap group of SJS and TEN, whereas TEN with maculae is the most severe type of skin reaction with more than 30% of skin detachment related to the body surface area (BSA). This classification was applied to cases of severe skin reactions in several large studies that have been undertaken within the last few years and published recently. The incidence of SJS, SJS/TEN overlap and TEN has been estimated to be approximately 1.89 cases per one million people per year. Although SJS and TEN occur very rarely, a mortality rate of more than 40% can be calculated for patients suffering from TEN. One may conclude that mortality increases with age and the amount of skin detachment related to the BSA. A number of drugs have been reported to induce severe skin reactions, eg, anti-infective sulfonamides, antibiotics, anticonvulsants and nonsteroidal anti-inflammatory drugs. For risk evaluation for certain drugs or drug groups population-based data as ascertained by the German registry of severe skin reactions, and prescription data in defined daily doses can be used. In addition, risk evaluation is possible by performing a case-control study as it has been undertaken within different European countries. As long as the pathogenesis of drug-induced severe skin reactions is not known, and specific screening methods to identify susceptible individuals do not exist, the epidemiological approach will remain the only possibility for risk estimation.

Entities:  

Mesh:

Year:  1996        PMID: 9069591     DOI: 10.1016/s1085-5629(96)80036-8

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  15 in total

1.  [Do sulfonamides still retain a place in dermatological therapy?].

Authors:  A Schnuch
Journal:  Hautarzt       Date:  2002-03       Impact factor: 0.751

2.  Should celecoxib be contraindicated in patients who are allergic to sulfonamides?

Authors:  Bengt-Erik Wiholm
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  [Detection and evaluation of adverse drug reactions].

Authors:  P A Thürmann; K Schmitt
Journal:  Med Klin (Munich)       Date:  1998-11-15

4.  Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

Authors:  Lois La Grenade; Lauren Lee; Joyce Weaver; Renan Bonnel; Claudia Karwoski; Laura Governale; Allen Brinker
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience.

Authors:  Rachel Forman; Gideon Koren; Neil H Shear
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Elizabeth Shay; Ahmad Kheirkhah; Lingyi Liang; Hossam Sheha; Darren G Gregory; Scheffer C G Tseng
Journal:  Surv Ophthalmol       Date:  2009-08-21       Impact factor: 6.048

7.  Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis.

Authors:  Nicole Mittmann; Sandra R Knowles; Manuel Gomez; Joel S Fish; Robert Cartotto; Neil H Shear
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

9.  Are Multimorbidities Underestimated in Scoring Systems of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Like in SCORTEN?

Authors:  Tobias von Wild; Peter L Stollwerck; Thomas Namdar; Felix H Stang; Peter Mailänder; Frank Siemers
Journal:  Eplasty       Date:  2012-08-02

Review 10.  Interventions for toxic epidermal necrolysis.

Authors:  S Majumdar; M Mockenhaupt; J- Roujeau; A Townshend
Journal:  Cochrane Database Syst Rev       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.